$BEAM News

B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

The FDA Clears Beam Therapeutics' Investigational New Drug Application For BEAM-304 For Phenylketonuria

Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?

Beam Therapeutics Stock Soars 21% in Three Months: Here's Why

Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International Conference - Slideshow

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock

Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

Beam Therapeutics Presented Clinical Data From Phase 1/2 Trial For BEAM-302 Treatment For Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference In Orlando, FL

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026